Astria Therapeutics has received FDA approval for its IND application concerning STAR-0310, a monoclonal antibody targeting OX40, aimed at treating atopic dermatitis.

Apogee Therapeutics has dosed the initial participants in a Phase 1 clinical trial for APG333.

NextCure, announced FDA approval of its IND application to begin a Phase 1 trial for LNCB74.

Protara reports favorable outcomes from the current Phase 2 ADVANCED-2 study of TARA-002 in NMIBC patients.

Affimed N.V. has revealed the oral presentation of AFM28 data at the 66th ASH Annual Meeting and Exposition.

Electra Therapeutics Shares Favorable Phase 1b Trial Outcomes for ELA026 in sHLH During an ASH 2024 Oral Presentation.

Immune-Onc Therapeutics Reveals Latest Phase 1b Trial Results for IO-202, Showcasing Positive Efficacy and Safety in CMML Patients, at the 2024 ASH Meeting.

Star Therapeutics Unveils Midpoint Clinical Results for VGA039 in VWD Patients at 2024 ASH Conference.

Auron Therapeutics has released data on its primary project, AUTX-703, at the 66th ASH Annual Meeting and Exposition in San Diego, CA.

Corbus Pharmaceuticals Begins First Human Trial of CRB-601 for Advanced Solid Tumors, Marking First Patient Dosed.

siRNA (small interfering RNA) drugs and ASO (antisense oligonucleotide) drugs, as the two pillars of the small nucleic acid therapeutics field.

Solu Therapeutics Reveals Favorable Preclinical Findings for STX-0712 in Treating Chronic Myelomonocytic and Acute Myeloid Leukemias at the ASH Conference.